Applied Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLT research report →
Range $0.25 – $4
Price Chart
About the company
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children.
- CEO
- Les D. Funtleyder
- IPO
- 2019
- Employees
- 35
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on APLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.86M
- P/E
- -0.24
- PEG
- -0.00
- P/S
- 14.86
- P/B
- -26.72
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
- Gross Margin
- -1676.00%
- Op Margin
- -6538.10%
- Net Margin
- -6214.50%
- ROE
- -348.18%
- ROIC
- -3371.89%
Latest fiscal year · YoY change
- Revenue
- $455.00K-95.4%
- Gross Profit
- $-48,289,000-10.0%
- Op Income
- $-104,299,000
- Net Income
- $-105,624,000+11.8%
- EPS
- $-0.76+46.5%
- OCF Growth
- -52.8%
- FCF Growth
- -52.8%
- 52W High
- $1.50
- 52W Low
- $0.09
- 50D MA
- $0.15
- 200D MA
- $0.46
- Beta
- 2.08
- RSI (14)
- 35
- Avg Volume
- 15.80M
No earnings-call transcripts are available for APLT yet.
- Free Float
- 83.0%
- Shares Outstanding
- 144.30M
- Float Shares
- 119.83M
of shares held by institutions
78 13F filers
Buy/sell ratio 0.04. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 6.35M | ▲ 1.25M |
| Point72 Asia (Singapore) Pte. Ltd. | 32.70K | ▲ 32.70K |
| Wolverine Trading, LLC | 20.41K | ▲ 20.41K |
| Quest Partners LLC | 4.66K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 3, 26 | Kanter Stacy J. | sell | 22,500 |
| Feb 3, 26 | Kanter Stacy J. | sell | 200,000 |
| Feb 3, 26 | Kanter Stacy J. | other | 42,500 |
| Feb 3, 26 | Kanter Stacy J. | sell | 16,500 |
| Dec 19, 25 | Hooks Corwin Dale | other | 312,500 |
| Feb 3, 26 | Hooks Corwin Dale | sell | 862,500 |
| Feb 3, 26 | Hooks Corwin Dale | other | 5,753 |
| Dec 19, 25 | Chinoporos Constantine | other | 437,500 |
| Feb 3, 26 | Chinoporos Constantine | sell | 1,000,000 |
| Feb 3, 26 | Chinoporos Constantine | other | 57,111 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APLT coverage
Recent articles, reports, and earnings notes.
No research on APLT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APLT report →Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis
defenseworld.net · Aug 20
Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
defenseworld.net · Feb 19
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
businesswire.com · Feb 3
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
businesswire.com · Jan 30
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
globenewswire.com · Jan 29
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
businesswire.com · Jan 29
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
businesswire.com · Jan 28
Applied Therapeutics Inc. (NASDAQ:APLT) Short Interest Update
defenseworld.net · Jan 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.